DebitMyData’s Human Energy Grid Reshapes Global AI and Data Infrastructure FORT LAUDERDALE, Fla., Oct. 24, 2025 (GLOBE NEWSWIRE) -- DebitMyData™ , Inc. today issues a crucial update for global ...
How to Apply Applications will soon be open globally on DAMAC’s platform www.damacislander.com where candidates can submit their creative entries explaining why they should be chosen as The Ultimate ...
Clariant, a sustainability-focused specialty chemical company, today announced that the Board of Directors decided to reduce its size from eleven to eight members, right-sizing the Board to align with ...
Bank of Åland Plc Interim Report October 24, 2025 9.00 EET. Interim Report for the period January - September 2024. Results ...
Toivo Group Plc (”Company” or ”Toivo”) has started the construction of a day care centre project valued at approximately EUR 4.5 million for Norlandia Päiväkodit Oy (”Norlandia”) in the Puustellinmäki ...
Amphista Therapeutics, a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the appointments of three senior leaders who will drive the ...
The right to nominate the members representing the shareholders belongs to the four shareholders whose share of the votes produced by all of Honkarakenne's shares, according to the shareholder list ...
In 2026, Digia will publish its Financial Statement Bulletin, two business reviews, and half-year interim report as follows: The Annual Report and financial statements for 2025 will be published on ...
EVLI PLC INTERIM REPORT, OCTOBER 24, 2025 AT 2:00 PM (EET/EEST) Evli Plc’s Interim Report January-September 2025 EXCELLENT THIRD QUARTER – ASSETS UNDER MANAGEMENT EXCEEDED EUR 20 BILLION Highlights of ...
The Shareholders' Nomination Committee of Solwers Plc consists of representatives appointed by the three largest shareholders according to the shareholder register dated 31 May 2025, as well as a ...
Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.
Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback